Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Should Dermatologists Manage Obesity in Psoriasis Patients?
Description
The presentation centers around the question of whether dermatologists should manage obesity in psoriasis patients. The speaker acknowledges the proficiency and extensive research of a fellow dermatologist, Mark, but emphasizes that dermatologists might not be the best suited to handle obesity management. They discuss various weight loss strategies including surgery and medications, highlighting the advancements in drug therapies. However, the speaker points out the challenges and risks associated with new medications, such as gastrointestinal side effects and potential serious complications like pancreatitis and links to cancer. They argue that while psoriasis patients often have multiple comorbidities, including metabolic syndrome and obesity, dermatologists should focus on their core expertise—understanding how psoriasis treatments affect weight and metabolic health, rather than venturing into broader obesity management. Ultimately, the presentation suggests that managing obesity and related metabolic conditions falls outside the primary role of dermatologists, who may lack the time and specific training to adequately address these issues.
View moreConclusions
- Dermatologists should be cautious when managing obesity in psoriasis patients as it involves complex interactions between skin conditions and metabolic health.
- Weight loss treatments, including medications like tirzepatide and semaglutide, can be effective but carry risks of significant side effects such as pancreatitis and gastrointestinal issues.
- Assessing the benefits and risks of obesity management strategies is crucial for dermatologists treating psoriasis patients in the context of comorbidities.
- Patient counseling before starting weight loss medications is essential for adherence and understanding potential adverse effects.
- Different patients may require tailored weight loss strategies considering their unique health profiles and comorbidities associated with psoriasis.
- Xie, Y. et al. (2024). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine
- Sodhi et al. (2023). GI risks of GLP-1RAs for weight loss. JAMA, 330(18), 1795-1796.
- Dowlatshahi EA, et al. J Invest Dermatol 2014;134:1542-51; Egeberg A, et al. Br J Dermatol 2019;180:116-21; Langan SM, et al. J Invest Dermatol 2012;132:556-62; Sommer DM, et al. Arch Dermatol Res 2006;298:321-28; Vlachos C, et al. Psoriasis (Auckl) 2016;6:73-92; Gelfand JM, et al. JAMA 2006;296:1735-41; Mansouri B, et al. JAMA Dermatol 2016;152:1244-53; Chiesa Fuxench ZC, et al. JAMA Dermatol 2016;152:282-90; Stern RS. J Rheumatol 1985;12:315-20.